Robert Hershberg

Dr. Robert M.
Hershberg is an Independent Director at Atai Beckley, Inc., a President at HilleVax, Inc., a Senior Advisor at Frazier Management LLC, an Executive Chairman at Cajal Therapeutics, a Vice Chairman at Recursion Pharmaceuticals, Inc., an Independent Director at Adaptive Biotechnologies Corp.
and a Member at UW Medicine.
He is on the Board of Directors at Danaher Corp., Atai Beckley, Inc., Beckley Psytech Ltd., Recursion Pharmaceuticals, Inc. and Adaptive Biotechnologies Corp.
Dr. Hershberg was previously employed as a Non-Executive Director by Atai Beckley NV, an Independent Director by Fate Therapeutics, Inc., an Independent Director by Silverback Therapeutics, Inc., an Independent Director by NanoString Technologies, Inc., a Chief Scientific Officer & Executive VP by Celgene Corp., a President, Chief Executive Officer & Director by VentiRx Pharmaceuticals, Inc., a Chief Medical Officer & Senior Vice President by Dendreon Corp., a Vice President-Medical Genetics by Corixa Corp., and an Assistant Professor by Harvard Medical School.
He also served on the board at Guide Therapeutics, Inc. He received his undergraduate degree from the University of California, Los Angeles, a doctorate degree from the The Salk Institute for Biological Studies and a doctorate degree from the University of California, Los Angeles.